WAIKOLOA, Hawaii — Patients with retinal diseases who were treated with anti-VEGF therapies through manufacturer patient assistance programs showed sustained vision gains and central subfield thickness reduction.
During a presentation at Retina 2026, Murtaza Adam, MD, FASRS, stressed that patients who are uninsured or underinsured often lack access to necessary anti-VEGF treatments like bevacizumab. However, manufacturer patient assistance programs (PAP) sponsored by companies like Regeneron and Genentech are designed to provide “free, charitable anti-VEGF therapy to patients that are in the